Targeting cancer stem-like cells (CSCs) further, Signal-Smart 2 (SS2), an engineered oHSV-1, was developed to selectively eliminate CD133+ cells, a subpopulation associated with tumor aggressiveness and therapeutic resistance. The gene discussed is PROM1; the disease is neoplasm.